Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Clene (NASDAQ:CLNN) in a research report sent to investors on Monday morning,Benzinga reports.

Separately, Weiss Ratings upgraded Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.

Clene Stock Up 0.8%

CLNN stock opened at $3.76 on Monday. The firm has a market cap of $48.84 million, a P/E ratio of -1.07 and a beta of 0.91. The company’s 50-day simple moving average is $3.98 and its 200-day simple moving average is $5.30. Clene has a 52-week low of $3.02 and a 52-week high of $13.50.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.06 million. On average, analysts anticipate that Clene will post -1.70 earnings per share for the current fiscal year.

Clene Company Profile

Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.

Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.